Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 424

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus-And Hepatitis C Virus-Coinfected Patients: Impact of Protease Inhibitor Therapy

Benhamou, Yves, Di Martino, Vincent, Bochet, Marie, Colombet, Geneviève, Thibault, Vincent, Liou, Amélie, Katlama, Christine, Poynard, Thierry·2001·Hepatology

Abstract

Hepatitis C virus (HCV)–related liver fibrosis progression is accelerated in human immunodeficiency virus (HIV)–infected patients. The effect of protease inhibitor (PI) therapy on liver fibrosis is unknown. The aim of this work was to analyze the impact of PI therapy on HCV–related liver fibrosis in HIV/HCV coinfected patients. We evaluated in a long–term follow–up retrospective cohort study the influence of antiretroviral therapy containing PI on liver fibrosis in 182 consecutive HIV/HCV coinfected patients. At liver biopsy, 63 patients had received PI and 119 patients had never been treated with PI. Relationships between liver histologic features, age, alcohol consumption, CD4 cell count, HIV–RNA load, and antiretroviral regimens were analyzed. Liver fibrosis stage was lower in patients receiving PIs by comparison with patients who had never received PIs (P = .03). The 5–, 15–, and 25–year cirrhosis rates were 2% versus 5%, 5% versus 18%, and 9% versus 27%, respectively, in patients who had received PIs compared with PI–untreated patients (P = .0006). Multivariate analysis identified 4 independent predictors of progression to cirrhosis: absence of protease inhibitor therapy (relative risk [RR] = 4.74, 95% confidence interval [CI], 1.34–16.67), heavy alcohol consumption (≥ 50 g daily) (RR = 4.71, 95% CI, 1.92–11.57), low CD4 cell count (<200/μL) (RR = 2.74, 95% CI, 1.17–6.41), and age at HCV contamination (≥20 years) (RR = 2.37, 95% CI, 1.04–5.38). In conclusion, protease inhibitor therapy might not accelerate progression to HCV–related cirrhosis. Furthermore, chronic use of antiretroviral therapy containing PI together with reduction of alcohol consumption and maintenance of high CD4 count could have a beneficial impact on liver fibrosis progression in HIV/HCV coinfected patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/jhep.2001.26517

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 424

Metadata

Authors
Benhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A., Katlama, C., & Poynard, T.
Venue
Hepatology
Published
2001-08
Volume
34
Issue
2
Pages
283-287
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2074424133
Cited by
424
References
15
FWCI
23.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus-And Hepatitis C Virus-Coinfected Patients: Impact of Protease Inhibitor Therapy. https://app.cochat.ai/papers/10.1053/jhep.2001.26517
The paper
Benhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A., Katlama, C., & Poynard, T. (2001). Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus-And Hepatitis C Virus-Coinfected Patients: Impact of Protease Inhibitor Therapy. Hepatology. https://doi.org/10.1053/jhep.2001.26517

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.